|
HE 20.3182/3:Am 3/4
|
Modeling the risk of adult T-cell leukemia/lymphoma in persons infected with human T-lymphotropic virus Type I / |
1 |
|
HE 20.3182/3:Am 3/5
|
Cancer drug discovery for the 1990s / |
1 |
|
HE 20.3182/3:Am 3/6
|
Heterogeneous expression in human tumors of anionic glutathione-S-transferase, a phase II enzyme associated with multidrug resistance / |
1 |
|
HE 20.3182/3:Am 3/7
|
Suramin, an active agent in metastatic adrenocortical carcinoma / |
1 |
|
HE 20.3182/3:Am 3/8
|
Reversal of alkylating agent and platinum resistance in ovarian cancer / |
1 |
|
HE 20.3182/3:At 6
|
New atlas maps U.S. cancer death rates for 1950-1980. |
1 |
|
HE 20.3182/3:B 77
|
Bristol-Myers licensed to test new AIDS drugs / |
1 |
|
HE 20.3182/3:C 99
|
Scientists discover new markers for cystic fibrosis. |
1 |
|
HE 20.3182/3:D 56
|
A followup study of mothers exposed to diethylstilbestrol in pregnancy / |
1 |
|
HE 20.3182/3:D 56/2
|
Recently reported health effects of exposure before birth and during pregnancy to the synthetic estrogen diethylstilbestrol (DES) |
1 |
|
HE 20.3182/3:D 84
|
Research on drug resistance at the National Cancer Institute. |
1 |
|
HE 20.3182/3:F 76
|
Cancer and formaldehyde : mortality among industrial workers. |
1 |
|
HE 20.3182/3:G 28
|
Genetic structure of AIDS virus now mapped. |
1 |
|
HE 20.3182/3:G 53
|
NCI sets goal for year 2000. |
1 |
|
HE 20.3182/3:H 75
|
Immunologic abnormalities among D.C. homosexuals with contacts from high-risk AIDS areas / |
1 |
|
HE 20.3182/3:In 8
|
Expanded NCI trials with IL-2 and LAK cells / |
1 |
|
HE 20.3182/3:M 31
|
Study shows mammography beneficial for women both over and under age 50. |
1 |
|
HE 20.3182/3:M 48/985
|
A Population at high risk for melanoma : hereditary melanoma and the dysplastic nevus syndrome. |
1 |
|
HE 20.3182/3:M 56
|
A step closer to understanding metastasis / |
1 |
|
HE 20.3182/3:M 72
|
NCI centers participating in modified group C IL-2/LAK program / |
1 |
